Here's the latest guidance for how to navigate the COVID-19 vaccination process for people receiving treatment for osteoporosis. nof.org/news/statement-join...
Some key takeaways:
- "Osteoporosis per se does not appear to increase the risk for infection with or complications from COVID-19. Therefore, it is not necessary to prioritize patients with osteoporosis for COVID-19 vaccination only on the basis of that condition."
- "Considering limited COVID-19 vaccine availability, vaccine dosing may need to be prioritized over potential slight alterations in standard osteoporosis regimens."
- "We recommend a one week interval between IV bisphosphonate infusion and COVID-19 vaccination ... ." (This includes Reclast and Boniva.)
- "We recommend an interval of 4-7 days between treatment with denosumab and COVID-19 vaccination to allow for the potential occurrence of injection site reactions with either treatment." (Denosumab is aka Prolia.)
